DeSombre E R, Jensen E V
Cancer. 1980 Dec 15;46(12 Suppl):2783-8. doi: 10.1002/1097-0142(19801215)46:12+<2783::aid-cncr2820461408>3.0.co;2-4.
Knowledge of the tumor content of estrogen receptor, called estrophilin, has proved to be of significant clinical value in human breast cancer. Although most breast cancer tissues contain cytosol estrophilin, essentially only patients whose cancers have moderate to high levels of estrophilin, designated estrophilin-rich, are found to respond to endocrine therapy. About two-thirds of patients with estrophilin-rich cancers obtain objective benefit from endocrine therapy. Present results indicate that predictions of response to endocrine therapy at time of recurrence can be based on the estrophilin assay of the primary lesion. Nonetheless, changes in estrophilin content during the course of disease are not uncommon. Despite an occasional patient in whom multiple samples separated by a long time have unchanged estrophilin content, there is a general tendency toward decreased estrophilin content with time.
已证明，了解雌激素受体（称为雌激素亲合蛋白）的肿瘤含量对人类乳腺癌具有重要的临床价值。虽然大多数乳腺癌组织都含有胞质雌激素亲合蛋白，但实际上只有那些癌症具有中度至高水平雌激素亲合蛋白（称为富含雌激素亲合蛋白）的患者才会对内分泌治疗有反应。约三分之二富含雌激素亲合蛋白癌症的患者可从内分泌治疗中获得客观益处。目前的结果表明，复发时对内分泌治疗反应的预测可以基于原发灶的雌激素亲合蛋白检测。然而，疾病过程中雌激素亲合蛋白含量的变化并不罕见。尽管偶尔有患者在长时间间隔采集的多个样本中雌激素亲合蛋白含量没有变化，但总体趋势是随着时间推移雌激素亲合蛋白含量会降低。
